These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38280382)

  • 1. Virological characteristics of the SARS-CoV-2 BA.2.86 variant.
    Tamura T; Mizuma K; Nasser H; Deguchi S; Padilla-Blanco M; Oda Y; Uriu K; Tolentino JEM; Tsujino S; Suzuki R; Kojima I; Nao N; Shimizu R; Wang L; Tsuda M; Jonathan M; Kosugi Y; Guo Z; Hinay AA; Putri O; Kim Y; Tanaka YL; Asakura H; Nagashima M; Sadamasu K; Yoshimura K; ; Saito A; Ito J; Irie T; Tanaka S; Zahradnik J; Ikeda T; Takayama K; Matsuno K; Fukuhara T; Sato K
    Cell Host Microbe; 2024 Feb; 32(2):170-180.e12. PubMed ID: 38280382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants.
    Tamura T; Ito J; Uriu K; Zahradnik J; Kida I; Anraku Y; Nasser H; Shofa M; Oda Y; Lytras S; Nao N; Itakura Y; Deguchi S; Suzuki R; Wang L; Begum MM; Kita S; Yajima H; Sasaki J; Sasaki-Tabata K; Shimizu R; Tsuda M; Kosugi Y; Fujita S; Pan L; Sauter D; Yoshimatsu K; Suzuki S; Asakura H; Nagashima M; Sadamasu K; Yoshimura K; Yamamoto Y; Nagamoto T; Schreiber G; Maenaka K; ; Hashiguchi T; Ikeda T; Fukuhara T; Saito A; Tanaka S; Matsuno K; Takayama K; Sato K
    Nat Commun; 2023 May; 14(1):2800. PubMed ID: 37193706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Virological characteristics of the SARS-CoV-2 Omicron BA.2.75 variant.
    Saito A; Tamura T; Zahradnik J; Deguchi S; Tabata K; Anraku Y; Kimura I; Ito J; Yamasoba D; Nasser H; Toyoda M; Nagata K; Uriu K; Kosugi Y; Fujita S; Shofa M; Monira Begum M; Shimizu R; Oda Y; Suzuki R; Ito H; Nao N; Wang L; Tsuda M; Yoshimatsu K; Kuramochi J; Kita S; Sasaki-Tabata K; Fukuhara H; Maenaka K; Yamamoto Y; Nagamoto T; Asakura H; Nagashima M; Sadamasu K; Yoshimura K; Ueno T; Schreiber G; Takaori-Kondo A; ; Shirakawa K; Sawa H; Irie T; Hashiguchi T; Takayama K; Matsuno K; Tanaka S; Ikeda T; Fukuhara T; Sato K
    Cell Host Microbe; 2022 Nov; 30(11):1540-1555.e15. PubMed ID: 36272413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Virological characteristics of the SARS-CoV-2 Omicron BA.2 spike.
    Yamasoba D; Kimura I; Nasser H; Morioka Y; Nao N; Ito J; Uriu K; Tsuda M; Zahradnik J; Shirakawa K; Suzuki R; Kishimoto M; Kosugi Y; Kobiyama K; Hara T; Toyoda M; Tanaka YL; Butlertanaka EP; Shimizu R; Ito H; Wang L; Oda Y; Orba Y; Sasaki M; Nagata K; Yoshimatsu K; Asakura H; Nagashima M; Sadamasu K; Yoshimura K; Kuramochi J; Seki M; Fujiki R; Kaneda A; Shimada T; Nakada TA; Sakao S; Suzuki T; Ueno T; Takaori-Kondo A; Ishii KJ; Schreiber G; ; Sawa H; Saito A; Irie T; Tanaka S; Matsuno K; Fukuhara T; Ikeda T; Sato K
    Cell; 2022 Jun; 185(12):2103-2115.e19. PubMed ID: 35568035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing the Infectivity of Recent SARS-CoV-2 Omicron Sub-Variants in Syrian Hamsters.
    Abdelnabi R; Lassaunière R; Maes P; Weynand B; Neyts J
    Viruses; 2024 Jan; 16(1):. PubMed ID: 38257822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spike mutations contributing to the altered entry preference of SARS-CoV-2 omicron BA.1 and BA.2.
    Hu B; Chan JF; Liu H; Liu Y; Chai Y; Shi J; Shuai H; Hou Y; Huang X; Yuen TT; Yoon C; Zhu T; Zhang J; Li W; Zhang AJ; Zhou J; Yuan S; Zhang BZ; Yuen KY; Chu H
    Emerg Microbes Infect; 2022 Dec; 11(1):2275-2287. PubMed ID: 36039901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple mutations of SARS-CoV-2 Omicron BA.2 variant orchestrate its virological characteristics.
    Kimura I; Yamasoba D; Nasser H; Ito H; Zahradnik J; Wu J; Fujita S; Uriu K; Sasaki J; Tamura T; Suzuki R; Deguchi S; Plianchaisuk A; Yoshimatsu K; Kazuma Y; Mitoma S; Schreiber G; Asakura H; Nagashima M; Sadamasu K; Yoshimura K; Takaori-Kondo A; ; Ito J; Shirakawa K; Takayama K; Irie T; Hashiguchi T; Nakagawa S; Fukuhara T; Saito A; Ikeda T; Sato K
    J Virol; 2023 Oct; 97(10):e0101123. PubMed ID: 37796123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Less neutralization evasion of SARS-CoV-2 BA.2.86 than XBB sublineages and CH.1.1.
    Hu Y; Zou J; Kurhade C; Deng X; Chang HC; Kim DK; Shi PY; Ren P; Xie X
    Emerg Microbes Infect; 2023 Dec; 12(2):2271089. PubMed ID: 37824708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The viral fitness and intrinsic pathogenicity of dominant SARS-CoV-2 Omicron sublineages BA.1, BA.2, and BA.5.
    Shuai H; Chan JF; Hu B; Chai Y; Yoon C; Liu H; Liu Y; Shi J; Zhu T; Hu JC; Hu YF; Hou Y; Huang X; Yuen TT; Wang Y; Zhang J; Xia Y; Chen LL; Cai JP; Zhang AJ; Yuan S; Zhou J; Zhang BZ; Huang JD; Yuen KY; To KK; Chu H
    EBioMedicine; 2023 Sep; 95():104753. PubMed ID: 37579626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Virological and Mitochondriopathogical Characteristics of the SARS-CoV-2 Omicron XBB.1.16 Spike.
    Fang L; Kang X; Hong Q; Xue C; Pan L; Chen J; Tang C; Sun L; Xu X; Yuan J; Du Y; Xu A
    ACS Appl Mater Interfaces; 2024 Jun; 16(23):29716-29727. PubMed ID: 38814480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The spike receptor-binding motif G496S substitution determines the replication fitness of SARS-CoV-2 Omicron sublineage.
    Liang R; Ye ZW; Ong CP; Qin Z; Xie Y; Fan Y; Tang K; Poon VK; Chan CC; Yang X; Cao H; Wang K; Sun H; Hu B; Cai JP; Luo C; Chik KK; Chu H; Zheng Y; Yuen KY; Chan JF; Jin DY; Yuan S
    Emerg Microbes Infect; 2022 Dec; 11(1):2093-2101. PubMed ID: 35943779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Virological characteristics of the SARS-CoV-2 Omicron EG.5.1 variant.
    Tsujino S; Deguchi S; Nomai T; Padilla-Blanco M; Plianchaisuk A; Wang L; Begum MM; Uriu K; Mizuma K; Nao N; Kojima I; Tsubo T; Li J; Matsumura Y; Nagao M; Oda Y; Tsuda M; Anraku Y; Kita S; Yajima H; Sasaki-Tabata K; Guo Z; Hinay AA; Yoshimatsu K; Yamamoto Y; Nagamoto T; Asakura H; Nagashima M; Sadamasu K; Yoshimura K; Nasser H; Jonathan M; Putri O; Kim Y; Chen L; Suzuki R; Tamura T; Maenaka K; Irie T; Matsuno K; Tanaka S; Ito J; Ikeda T; Takayama K; Zahradnik J; Hashiguchi T; Fukuhara T; Sato K;
    Microbiol Immunol; 2024 Jul; ():. PubMed ID: 38961765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Biological Functions and Clinical Significance of SARS-CoV-2 Variants of Corcern.
    Akkız H
    Front Med (Lausanne); 2022; 9():849217. PubMed ID: 35669924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Virological characteristics of the SARS-CoV-2 Omicron XBB.1.5 variant.
    Tamura T; Irie T; Deguchi S; Yajima H; Tsuda M; Nasser H; Mizuma K; Plianchaisuk A; Suzuki S; Uriu K; Begum MM; Shimizu R; Jonathan M; Suzuki R; Kondo T; Ito H; Kamiyama A; Yoshimatsu K; Shofa M; Hashimoto R; Anraku Y; Kimura KT; Kita S; Sasaki J; Sasaki-Tabata K; Maenaka K; Nao N; Wang L; Oda Y; ; Ikeda T; Saito A; Matsuno K; Ito J; Tanaka S; Sato K; Hashiguchi T; Takayama K; Fukuhara T
    Nat Commun; 2024 Feb; 15(1):1176. PubMed ID: 38332154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SARS-CoV-2 Omicron XBB subvariants exhibit enhanced fusogenicity and substantial immune evasion in elderly population, but high sensitivity to pan-coronavirus fusion inhibitors.
    Xia S; Jiao F; Wang L; Yu X; Lu T; Fu Y; Huang Z; Li X; Huang J; Wang Q; Man Q; Xiong L; Jiang S; Lu L
    J Med Virol; 2023 Mar; 95(3):e28641. PubMed ID: 36890632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of a SARS-CoV-2 EG.5.1 clinical isolate in vitro and in vivo.
    Uraki R; Kiso M; Iwatsuki-Horimoto K; Yamayoshi S; Ito M; Chiba S; Sakai-Tagawa Y; Imai M; Kashima Y; Koga M; Fuwa N; Okumura N; Hojo M; Iwamoto N; Kato H; Nakajima H; Ohmagari N; Yotsuyanagi H; Suzuki Y; Kawaoka Y
    Cell Rep; 2023 Dec; 42(12):113580. PubMed ID: 38103202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Analysis of Conformational Dynamics and Systematic Characterization of Cryptic Pockets in the SARS-CoV-2 Omicron BA.2, BA.2.75 and XBB.1 Spike Complexes with the ACE2 Host Receptor: Confluence of Binding and Structural Plasticity in Mediating Networks of Conserved Allosteric Sites.
    Alshahrani M; Gupta G; Xiao S; Tao P; Verkhivker G
    Viruses; 2023 Oct; 15(10):. PubMed ID: 37896850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune evasion, infectivity, and fusogenicity of SARS-CoV-2 BA.2.86 and FLip variants.
    Qu P; Xu K; Faraone JN; Goodarzi N; Zheng YM; Carlin C; Bednash JS; Horowitz JC; Mallampalli RK; Saif LJ; Oltz EM; Jones D; Gumina RJ; Liu SL
    Cell; 2024 Feb; 187(3):585-595.e6. PubMed ID: 38194968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Reinfection with SARS-CoV-2 Omicron Variants in Previously Infected Hamsters.
    Shiwa-Sudo N; Sakai Y; Iwata-Yoshikawa N; Watanabe S; Yamada S; Kuroda Y; Yamamoto T; Shirakura M; Fujisaki S; Miyazaki K; Miura H; Nagata S; Fukushi S; Maeda K; Hasegawa H; Suzuki T; Nagata N
    J Virol; 2023 Jan; 97(1):e0136622. PubMed ID: 36633406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Virological features and pathogenicity of SARS-CoV-2 Omicron BA.2.
    Chan JF; Hu B; Chai Y; Shuai H; Liu H; Shi J; Liu Y; Yoon C; Zhang J; Hu JC; Hou Y; Huang X; Yuen TT; Zhu T; Li W; Cai JP; Luo C; Yip CC; Zhang AJ; Zhou J; Yuan S; Zhang BZ; Huang JD; To KK; Yuen KY; Chu H
    Cell Rep Med; 2022 Sep; 3(9):100743. PubMed ID: 36084644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.